NewsBenzingaArcturus Therapeutics To Present Overview Of ARCT-810 Phase 2 Clinical Program For Ornithine Transcarbamylase Deficiency And Arcturus’ mRNA Liver Therapeutics Platform On Sept. 23 Arcturus Therapeutics To Present Overview Of ARCT-810 Phase 2 Clinical Program For Ornithine Transcarbamylase Deficiency And Arcturus’ mRNA Liver Therapeutics Platform On Sept. 23 Benzinga 2026.09.18 13:04 (GMT+0) Open on Benzinga Other news BTIG Reiterates Buy on Nexxen International, Maintains $13 Price Target Morgan Stanley Maintains Equal-Weight on Xcel Energy, Raises Price Target to $85 Morgan Stanley Maintains Equal-Weight on Western Midstream, Lowers Price Target to $52 Morgan Stanley Maintains Overweight on Vistra, Lowers Price Target to $226 Alaska Air Gr Q3 2026 Earnings Call Transcript If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
